Soquelitinib, Corvus Pharmaceuticals’ immune-modulating investigational oral treatment for autoimmune diseases and certain cancers, reduced the signs and symptoms of lung disease caused by systemic sclerosis (SSc), according to new preclinical data. Designed to selectively block ITK, an enzyme predominantly found in immune T-cells, soquelitinib suppresses Th2 cells —…
Cells derived from people with systemic sclerosis (SSc) had widespread DNA mutations compared with healthy cells, which may explain the higher risk of cancer in this patient population, according to a study. Changes included mutational patterns found solely in the genomes of certain cancers, as well as changes in…
A chest CT scan taken before a lung transplant can help predict survival after the transplant in people with systemic sclerosis (SSc), a new U.S. study suggests. Muscle mass, bone density, and the volume of the heart and blood vessels were among the “novel image features” of the pretransplant…
Problems with the heart’s left ventricle at a subclinical — not yet symptomatic and overt — level were evident in 1 in every 4 people with systemic sclerosis (SSc) taking part in an Australian study when a potentially more sensitive measure than left ventricle ejection fraction was used. Both…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cabaletta Bio’s cell therapy CABA-201 as a treatment for adults with hard-to-treat systemic sclerosis (SSc), or scleroderma. Orphan drug designation is intended to support the accelerated development of investigational treatments for rare diseases, defined as…
More conversations, either one on one or in groups via telephone or virtually, along with in-person household activities and conversations, were significantly associated with less loneliness during the COVID-19 pandemic among people with systemic sclerosis (SSc), a study indicates. Conversations and activities at the…
Dosing has begun in a Phase 2 clinical trial evaluating aTyr Pharma’s efzofitimod, a first-in-class therapy for people with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) — together known as SSc-ILD. Recruitment for the proof-of-concept EFZO-CONNECT study (NCT05892614), which aims to enroll up to 25…
The U.S. Food and Drug Administration (FDA) has cleared Cabaletta Bio’s request to begin clinical testing of CABA-201, a cell therapy for adults with hard-to-treat systemic sclerosis (SSc). Cabaletta now plans to launch a Phase 1/2 clinical trial, enrolling SSc patients with severe skin manifestations or organ…
The levels of two microRNAs are found altered in the bloodstream of adults with systemic sclerosis (SSc) compared with healthy people, according to a new study that suggests using these molecules as biomarkers of the disease. Elevated levels of one of them, called miR-21, is associated with scar formation,…
People with systemic sclerosis (SSc) have a wide range of support and information needs, regardless of their disease duration, a survey found. Patients with less time since diagnosis had greater needs overall and in areas of learning how to manage their condition and how to cope psychologically and socially.
Get regular updates to your inbox.